13F Holdings
中文EN

TRDA Entrada Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%

Returns

ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$25.42M$210.78M$129.01M——
R&D expense$142.27M$125.31M$99.88M$66.61M$35.93M
SG&A expense$41.05M$38.47M$32.29M$30.64M$15.20M
Operating income-$157.90M$47.01M-$3.16M-$97.25M-$51.13M
Income tax$924,000$859,000$18.74M$0$0
Net income-$143.75M$65.63M-$6.68M-$94.62M-$51.16M
EBITDA-$153.80M$50.78M-$321,000-$95.35M-$50.01M
EPS (basic)-3.471.76-0.20-3.02-8.16
EPS (diluted)-3.471.68-0.20-3.02-8.16
Weighted avg. shares (diluted)41.37M39.00M33.05M31.29M6.27M
Balance sheet
Cash & equivalents$90.39M$105.16M$71.55M$49.11M$291.06M
Short-term investments————$0
Current assets$306.25M$440.04M$369.77M$209.88M$298.70M
PP&E, net$7.31M$10.93M$11.19M$7.68M$6.26M
Total assets$377.38M$526.32M$469.19M$252.06M$305.83M
Current liabilities$24.45M$39.48M$158.80M$21.97M$6.72M
Total liabilities$71.25M$97.64M$226.83M$39.50M$7.12M
Shareholders' equity$306.13M$428.68M$242.36M$212.55M$298.72M
Shares outstanding38.28M37.57M33.44M31.39M31.22M
Cash flow statement
Operating cash flow-$128.51M-$41.56M$139.80M-$93.79M-$50.86M
Capital expenditure$1.04M$3.16M$5.61M$2.89M$4.58M
Free cash flow-$129.55M-$44.72M$134.19M-$96.67M-$55.44M
Investing cash flow$116.81M-$27.80M-$138.40M-$148.65M-$4.58M
Financing cash flow$887,000$102.96M$21.04M$479,000$307.46M
Depreciation & amortization$4.10M$3.77M$2.84M$1.90M$1.12M
Stock-based compensation$19.61M$17.91M$13.11M$9.89M$2.53M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.